Paeds SAQs · genetics-dysmorphology-and-metabolism
Mucopolysaccharidoses and oligosaccharidoses — formative SAQs
Formative SAQs on the mucopolysaccharidoses and oligosaccharidoses: recognising the coarse-facies phenotype with dysostosis multiplex, grouping the subtypes by stored substrate and the discriminating cornea-versus-intellect signs, confirming with a layered urine-and-enzyme-and-genotype workup, and matching the disease-modifying therapy to central-nervous-system involvement.
On this page & tools
Target exams
Question 1 (10 marks)
A three-year-old boy who appeared normal at birth is referred for progressive coarsening of the facial features, persistent umbilical hernia, snoring, and slowing of speech. Examination reveals macroglossia, hepatosplenomegaly with the liver edge 4 cm below the costal margin, claw-hand deformity, and a thoracolumbar gibbus. A skeletal survey shows dysostosis multiplex. The cornea is clear and he is a boy. [1] [2]
(a) Give the most likely disorder family and the single most discriminating bedside feature pointing to the subtype, justifying why the clear cornea matters. (3 marks) [1]
(b) Outline the stepwise confirmatory investigation strategy, naming the first-line screening test, the confirmatory enzyme test, and the molecular test, and explain how the urinary glycosaminoglycan pattern is used. (4 marks) [1] [2]
(c) Explain why the treatment modality depends on whether the central nervous system is involved, naming the two principal disease-modifying options and the constraint on each. (3 marks) [2] [3]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References4Show ledgerHide ledger
- [1]Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford), 2011.PMID 22210669
- [2]Wraith JE. Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol, 2013.PMID 23622395
- [3]Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med, 2006.PMID 16912578
- [4]Gentner B, Tucci F, Galimberti S, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med, 2021.PMID 34788506